PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1413767
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1413767
The global vascular endothelial growth factor (VEGF) market is on the cusp of significant growth, with a valuation of US$ 245 million at the close of 2024. By the end of 2031, the VEGF market is estimated to reach a substantial valuation of US$ 560 million, indicating a highly progressive growth trajectory.
The versatility of VEGF molecules and advancements in research exploring their benefits in disease intervention have led to substantial growth in the market. Studies have demonstrated the potential of VEGF in treating renovascular disease (RVD) by coupling it with innovative carrier proteins. Enhanced renal function, reduced vascular resistance, and improved microvascular density have all been associated with VEGF-based treatments.
Investments in clinical trial investigations are expected to increase in the coming years, further bolstering market growth. Additionally, the use of intradermal VEGF-A mRNA in regenerative angiogenesis shows promise as a treatment for ischemic cardiovascular disease and diabetes, expanding the VEGF market from clinical interventions to a consumer-driven market.
One of the notable opportunities for VEGF manufacturers lies in the treatment of peripheral vascular diseases. Recent research into gene co-delivery nanoparticles containing VEGF and nerve growth factors has shown promising results in improving blood perfusion, gene co-expression, and stable angiogenesis, offering new treatment options for peripheral vascular diseases.
Poly-l-lactide (PLA) loaded VEGF microparticles with a long-term release structure also hold potential in proangiogenic therapy, reducing the negative effects of multiple administrations and aiding in tissue remodeling, vasculogenesis, and angiogenesis.
The wide range of applications for VEGF presents lucrative opportunities for market players, with a growing trend in demand and sales.
Despite its potential, the short half-life of VEGF protein and challenges in selecting the route of administration for drug delivery have hindered its clinical success. Overcoming the limitations of VEGF's short half-life and chemical instability remains a challenge in the manufacturing process.
U.S. VEGF Market: The U.S. dominated the North American VEGF market in 2024. Acquisitions by manufacturers and a growing focus on better treatment options have contributed to market growth.
German VEGF Market: Germany held a significant portion of the market share in Europe's vascular endothelial growth factor market in 2024.
The prominent players in Germany are actively expanding their manufacturing centers to offer products at competitive prices within the region, thereby playing a pivotal role in driving the growth of the German market.
China VEGF Market: In 2024, China held a significant market share in the East Asian vascular endothelial growth factor market.
Chinese leaders are increasingly viewing biologic contract manufacturing organizations (CMOs) as a viable option for bio manufacturing. These CMOs offer services to small- and medium-sized companies and invest in GMP facilities, making them an attractive choice.
Furthermore, established companies are expanding their manufacturing facilities, further bolstering the growth of the market in China.